Xeris Biopharma Holdings, Inc. (FRA:2B30)

Market Cap	930.93M +77.3%
Revenue (ttm)	226.83M +42.0%
Net Income	-13.33M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	30.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	5.63
Previous Close	5.87
Day's Range	5.63 - 5.63
52-Week Range	3.42 - 8.48
Beta	n/a
RSI	40.19
Earnings Date	Mar 2, 2026

About Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adul...

• Industry: Pharmaceutical Preparations
• Founded: 2005
• Employees: 394
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2B30

Financial Performance

In 2024, Xeris Biopharma Holdings's revenue was $203.07 million, an increase of 23.89% compared to the previous year's $163.91 million. Losses were -$54.84 million, -11.92% less than in 2023.

Financial numbers in USD